Different features of the DNA binding mode of antitumor cis -amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro

Chemical Research in Toxicology

Volumn 23, Issue 11, 2010, Pages 1833-1842

  Kostrhunova, Hana ^a   Vrana, Oldrich ^a   Suchankova, Tereza ^b   Gibson, Dan ^c   Kasparkova, Jana ^a   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CISPLATIN; CURVED DNA; CYCLOHEXYLAMINE; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; SATRAPLATIN;

ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; CROSS LINKING; DNA ADDUCT; DNA BINDING; DNA CONFORMATION; DNA DENATURATION; DNA REPAIR; DNA SYNTHESIS; DRUG DNA BINDING; DRUG STRUCTURE; PROTEIN DNA INTERACTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CIRCULAR DICHROISM; CISPLATIN; DNA; DNA ADDUCTS; DNA REPAIR; HUMANS; NUCLEIC ACID DENATURATION; ORGANOPLATINUM COMPOUNDS; TRANSITION TEMPERATURE;

EID: 78649257602     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx1002904     Document Type: Article

References (75)

1. Johnson, N. P., Butour, J.-L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., and Brabec, V. (1989) Metal antitumor compounds: The mechanism of action of platinum complexes Prog. Clin. Biochem. Med. 10, 1-24
2. Jamieson, E. R. and Lippard, S. J. (1999) Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 99, 2467-2498
3. Vrana, O., Brabec, V., and Kleinwächter, V. (1986) Polarographic studies on the conformation of some platinum complexes: relations to anti-tumour activity Anti-Cancer Drug Des. 1, 95-109
4. Farrell, N., Kelland, L. R., Roberts, J. D., and Van Beusichem, M. (1992) Activation of the trans geometry in platinum antitumor complexes: A Survey of the cytotoxicity of trans complexes containing planar ligands in murine-L1210 and human tumor panels and studies on their mechanism of action Cancer Res. 52, 5065-5072
5. Aris, S. M. and Farrell, N. P. (2009) Towards antitumor active trans-platinum compounds Eur. J. Inorg. Chem. 2009, 1293-1302
6. Hollis, L. S., Sundquist, W. I., Burstyn, J. N., Heiger-Bernays, W. J., Bellon, S. F., Ahmed, K. J., Amundsen, A. R., Stern, E. W., and Lippard, S. J. (1991) Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents Cancer Res. 51, 1866-1875
7. + Mol. Pharmacol. 53, 846-855
8. Lovejoy, K. S., Todd, R. C., Zhang, S. Z., McCormick, M. S., D'Aquino, J. A., Reardon, J. T., Sancar, A., Giacomini, K. M., and Lippard, S. J. (2008) cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects Proc. Natl. Acad. Sci. U.S.A. 105, 8902-8907
9. Farrell, N. (2004) Polynuclear Platinum Drugs, in Metal Ions in Biological Systems (Sigel, A. and Sigel, H., Eds.) pp 251 - 296, Marcel Dekker, Inc., New York.
10. Wheate, N. J. and Collins, J. G. (2005) Multi-nuclear platinum drugs: A new paradigm in chemotherapy Curr. Med. Chem.-Anti-Cancer Agents 5, 267-279
11. Hall, M. D., Mellor, H. R., Callaghan, R., and Hambley, T. W. (2007) Basis for design and development of platinum(IV) anticancer complexes J. Med. Chem. 50, 3403-3411
12. Bednarski, P. J., Mackay, F. S., and Sadler, P. (2007) Photoactivatable platinum complexes Anti-Cancer Agents Med. Chem. 7, 75-93
13. Wong, E. and Giandomenico, C. M. (1999) Current status of platinum-based antitumor drugs Chem. Rev. 99, 2451-2466
14. Brabec, V. and Kasparkova, J. (2005) DNA Interactions of Platinum Anticancer Drugs. Recent Advances and Mechanisms of Action, in Metal Compounds in Cancer Chemotherapy (Perez-Martin, J.-M., Fuertes, M. A., and Alonso, C., Eds.) pp 187 - 218, Research Signpost, Trivandrum, India.
15. Raynaud, F. I., Boxall, F. E., Goddard, P., Barnard, C. F., Murrer, B. A., and Kelland, L. R. (1996) Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products Anticancer Res. 16, 1857-1862
16. O'Neill, C. F., Hunakova, L., and Kelland, L. R. (1999) Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells Chem.-Biol. Interact 123, 11-29
17. Fokkema, E., Groen, H. J. M., Helder, M. N., deVries, E. G. E., and Meijer, C. (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin Biochem. Pharmacol. 63, 1989-1996
18. Wosikowski, K., Lamphere, L., Unteregger, G., Jung, V., Kaplan, F., Xu, J., Rattel, B., and Caligiuri, M. (2007) Preclinical antitumor activity of the oral platinum analog satraplatin Cancer Chemother. Pharmacol. 60, 589-600
19. Kelland, L. (2007) Broadening the clinical use of platinum drug-based chemotherapy with new analogues: satraplatin and picoplatin Expert Opin. Invest. Drugs 16, 1009-1021
20. Hall, M. D. and Hambley, T. W. (2002) Platinum(IV) antitumour compounds: their bioinorganic chemistry Coord. Chem. Rev. 232, 49-67
21. McA'Nulty, M. M. and Lippard, S. J. (1996) The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast Mutat. Res. 362, 75-86
22. Jung, Y. and Lippard, S. J. (2007) Direct cellular responses to platinum-induced DNA damage Chem. Rev. 107, 1387-1407
23. Vaisman, A., Lim, S. E., Patrick, S. M., Copeland, W. C., Hinkle, D. C., Turchi, J. J., and Chaney, S. G. (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts Biochemistry 38, 11026-11039
24. Wei, M., Cohen, S. M., Silverman, A. P., and Lippard, S. J. (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins J. Biol. Chem. 276, 38774-38780
25. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. (1996) The role of DNA mismatch repair in platinum drug resistance Cancer Res. 56, 4881-4886 (Pubitemid 26374423)
26. Choy, H., Park, C., and Yao, M. (2008) Current status and future prospects for satraplatin, an oral platinum analogue Clin. Cancer Res. 14, 1633-1638
27. 2, a metabolite of an orally active platinum anticancer drug J. Am. Chem. Soc. 114, 5646-5654
28. Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Bernard, C. F. J., Harrap, K. R., Goddard, P. M., Kelland, L. R., and Morgan, S. E. (1991) Synthesis and Reactions of a New Class of Orally Active Pt(IV) Antitumor Complexes, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (Howell, S. B., Ed.) pp 93 - 100, Plenum Press, New York.
29. Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Rheinheimer, M. I., Wyer, S. B., Bossard, G. E., and Higgins, J. D. (1995) Carboxylation of kinetically inert platinum(IV) hydroxy complexes: An entree into orally-active platinum(IV) antitumor agents Inorg. Chem. 34, 1015-1021
30. Brabec, V. and Palecek, E. (1970) The influence of salts and pH on polarographic currents produced by denatured DNA Biophysik 6, 290-300
31. Brabec, V. and Palecek, E. (1976) Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides Biophys. Chem. 4, 76-92
32. Manley, J. L., Fire, A., Cano, A., Sharp, P. A., and Gefter, M. L. (1980) DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract Proc. Natl. Acad. Sci. U.S.A. 77, 3855-3859
33. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res. 59, 3968-3971
34. Kim, S. D., Vrana, O., Kleinwächter, V., Niki, K., and Brabec, V. (1990) Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA Anal. Lett. 23, 1505-1518
35. Brabec, V., Sip, M., and Leng, M. (1993) DNA conformational distortion produced by site-specific interstrand cross-link of trans- diamminedichloroplatinum(II) Biochemistry 32, 11676-11681
36. Kasparkova, J., Mellish, K. J., Qu, Y., Brabec, V., and Farrell, N. (1996) Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies Biochemistry 35, 16705-16713
37. Brabec, V. and Leng, M. (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues Proc. Natl. Acad. Sci. U.S.A. 90, 5345-5349
38. Farrell, N., Qu, Y., Feng, L., and Van Houten, B. (1990) Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues Biochemistry 29, 9522-9531
39. Butour, J. L. and Macquet, J. P. (1977) Differentiation of DNA-platinum complexes by fluorescence. The use of an intercalating dye as a probe Eur. J. Biochem. 78, 455-463
40. 2] Eur. J. Biochem. 202, 975-980
41. Keck, M. V. and Lippard, S. J. (1992) Unwinding of supercoiled DNA by platinum ethidium and related complexes J. Am. Chem. Soc. 114, 3386-3390
42. Koo, H. S., Wu, H. M., and Crothers, D. M. (1986) DNA bending at adenine.thymine tracts Nature 320, 501-506
43. + Biophys. Chem. 35, 179-188
44. Kasparkova, J., Farrell, N., and Brabec, V. (2000) Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes J. Biol. Chem. 275, 15789-15798
45. II complexes containing aromatic linkers Biochem. Pharmacol. 80, 344-351
46. Wood, R. D., Robins, P., and Lindahl, T. (1988) Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts Cell 53, 97-106
47. Manley, J. L., Fire, A., Samuels, M., and Sharp, P. A. (1983) In Vitro transcription: Whole-cell extract Methods Enzymol. 101, 568-582
48. Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22, 7265-7279
49. Coluccia, M., Nassii, F., Loseto, F., Boccarelli, A., Marigió, M. A., Giordano, D., Intini, F. P., Caputo, P., and Natile, G. (1993) A trans-platinum complex showing higher antitumor activity than the cis congeners J. Med. Chem. 36, 510-512
50. II complex resistant to decomposition by sulfur nucleophiles Biochem. Pharmacol. 79, 112-121
51. 2] Nucleic Acids Res. 24, 336-341
52. 3)(quinoline)] Eur. J. Biochem. 254, 547-557
53. Brabec, V., Kasparkova, J., Vrana, O., Novakova, O., Cox, J. W., Qu, Y., and Farrell, N. (1999) DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent Biochemistry 38, 6781-6790
54. Brabec, V., Kleinwächter, V., Butour, J. L., and Johnson, N. P. (1990) Biophysical studies of the modification of DNA by antitumour platinum coordination complexes Biophys. Chem. 35, 129-141
55. Bancroft, D. P., Lepre, C. A., and Lippard, S. J. (1990) 195Pt NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA J. Am. Chem. Soc. 112, 6860-6871
56. Vrana, O., Kleinwächter, V., and Brabec, V. (1984) Polarographic activity of the antitumor drug cis-dichlorodiammineplatinum(II). The effect of hydrolysis and trans-isomerization of the drug Experientia 40, 446-451
57. Cohen, S. M. and Lippard, S. J. (2001) Cisplatin: From DNA damage to cancer chemotherapy Prog. Nucleic Acid Res. Mol. Biol. 67, 93-130
58. Malina, J., Novakova, O., Vojtiskova, M., Natile, G., and Brabec, V. (2007) Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog Biophys. J. 93, 3950-3962
59. Kostrhunova, H. and Brabec, V. (2000) Conformational analysis of site-specific DNA cross-links of cisplatin-distamycin conjugates Biochemistry 39, 12639-12649
60. Malina, J., Hofr, C., Maresca, L., Natile, G., and Brabec, V. (2000) DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands Biophys. J. 78, 2008-2021
61. Stehlikova, K., Kostrhunova, H., Kasparkova, J., and Brabec, V. (2002) DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent Nucleic Acids Res. 30, 2894-2898
62. Kasparkova, J., Zehnulova, J., Farrell, N., and Brabec, V. (2002) DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair J. Biol. Chem. 277, 48076-48086
63. 3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts Biochemistry 42, 792-800
64. Bellon, S. F., Coleman, J. H., and Lippard, S. J. (1991) DNA unwinding produced by site-specific intrastrand cross- links of the antitumor drug cis-diamminedichloroplatinum(II) Biochemistry 30, 8026-8035
65. Rice, J. A., Crothers, D. M., Pinto, A. L., and Lippard, S. J. (1988) The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by ∼40° toward the major groove Proc. Natl. Acad. Sci. U.S.A. 85, 4158-4161
66. Ulanovsky, L., Bodner, M., Trifonov, E. N., and Choder, M. (1986) Curved DNA: Design, synthesis, and circularization Proc. Natl. Acad. Sci. U.S.A. 83, 862-866
67. 2)) with guanosine 5′-monophosphate Aust. J. Chem. 52, 173-177
68. Mellish, K. J., Barnard, C. F. J., Murrer, B. A., and Kelland, L. R. (1995) DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines Int. J. Cancer 62, 717-723
69. Parker, R. J., Dimery, I. W., Dabholkar, M., Vionnet, J., and Reed, E. (1993) Platinum-DNA adduct in head and neck-cancer patients receiving cisplatin and carboplatin chemotherapy Int. J. Oncol. 3, 331-335
70. Ohndorf, U. M., Rould, M. A., He, Q., Pabo, C. O., and Lippard, S. J. (1999) Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins Nature 399, 708-712
71. 2+ bound to a dodecamer DNA complex J. Biol. Chem. 277, 49743-49749
72. 2{d(pGpG)} ], the principal adduct formed by cis -diamminedichloroplatinum(II) with DNA J. Am. Chem. Soc. 110, 7368-7380
73. Kartalou, M. and Essigmann, J. M. (2001) Recognition of cisplatin adducts by cellular proteins Mutat. Res. 478, 1-21
74. Zamble, D. B. and Lippard, S. J. (1999) The Response of Cellular Proteins to Cisplatin-Damaged DNA, in Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B., Ed.) pp 73 - 110, VHCA, WILEY-VCH, Zürich, Switzerland.
75. Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation Biochemistry 24, 707-713